Introduction
In spite of the availability, since 1981, of a safe and effective vaccine against hepatitis B, the overall incidence of hepatitis B virus infection changed little through 1988. Among heterosexuals and intravenous drug users, the incidence of hepatitis B increased.' The strategy for hepatitis B prevention has been to vaccinate all groups at high risk for infection2; through 1992, however, 80% of those who received the vaccine were health care workers. In this risk group, hepatitis B decreased by 75%.1 In the current study, we examined the feasibility of vaccinating persons attending a clinic for sexually transmitted diseases, another group that has been shown to be at high risk of hepatitis B virus infection. This group has been identified as one that should be targeted for hepatitis B vaccination2, 3; however, this is not now routine practice in the United States. Our study involved estimation of the number of hepatitis B virus infections that could be prevented through routine vaccination as well as cost analyses comparing different strategies for vaccinating this population.
Methods not return for scheduled doses within 2 weeks were contacted by telephone.
Mantel-Haenszel chi-square tests were used to evaluate demographic and hepatitis B virus risk factors potentially associated with initial hepatitis B vaccine acceptance and return for at least one follow-up vaccine dose. Logistic regression analyses were performed to control for possible confounding factors; logistic models included all factors found to be statistically significant in the respective univariate analyses as well as factors associated with hepatitis B virus in a separate analysis (data not shown). Results from the full logistic models are presented.
While two doses of vaccine have been shown to induce protective levels of antibody (greater than 10 mIU/mL of anti-HBs) in 80% of vaccine recipients,4 we estimated vaccine-induced protection to be 70% when only two doses were received. We assumed vaccine-induced protection to be 85% for patients receiving three doses at 0, 1, and 6 months.5 For patients receiving only one dose of vaccine, we assumed that no protection was provided. We assumed permanent protection in patients for whom vaccine was efficacious, although the exact duration of protection has not been established. The high prevalence of anti-HBc observed in this population suggests that these clinic patients are at higher risk for hepatitis B virus infection than health care workers. The 44% acceptance of at least one dose of vaccine in this population, not previously targeted by educational programs, is comparable to that reported among health care workers (a group relatively easy to reach and medically educated) in the first years that they were targeted for vaccination. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Our results show that patient behavior must be considered when evaluating the benefits of a vaccine program. For example, return rates among patients scheduled to receive a third dose at 2 months were not significantly greater than those among patients receiving a third dose at 6 months, suggesting that a dose at 6 months, which produces a greater antibody response,16'17 may be more advantageous in this population. Importantly, it would eliminate the need for a fourth vaccine dose.
The cost analysis described here, using findings from an actual program and thereby considering the effects of patient behavior, is able to demonstrate the relative costs of different vaccination strategies in one population. Vaccinating patients less than 25 years of age appears to be the most cost-effective strategy; however, given the considerably larger number of infections prevented by vaccinating all patients, vaccinating all susceptible patients would be more beneficial and may be more practical overall. Similarly, delivering a first dose of vaccine prior to determining susceptibility would prevent a greater number of infections.
Although 
